Moderate to Severe Asthma Clinical Trial
Official title:
Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics
Purpose: To determine if inhaled hypertonic saline (HS) accelerates airway mucociliary clearance (MCC) in well-controlled moderate to severe asthmatics.
Participants: Non-smoking adults with well controlled moderate to severe asthma Procedures (methods): After undergoing a general health screen, participants will undergo a lung transmission scan to create an image of the lungs. In subsequent visits, participants will inhale nebulized radiolabeled aerosol and sit in front of a gamma camera for 2 hours to measure clearance of radiolabeled particles from the lungs (procedure called gamma scintigraphy), which will be used to calculate baseline MCC. Spirometry will be performed before and at regular intervals after HS to assess for clinically significant reductions in lung function. Vital signs and symptom questionnaires will be administered as well. If participants are deemed tolerant to HS (i.e., no clinically significant deterioration in lung function, vital signs, or symptom questionnaire scores), participants will move forward with study visits. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05774340 -
A Study of CM326 in Subjects With Moderate to Severe Asthma
|
Phase 2 | |
| Recruiting |
NCT05851443 -
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
|
Phase 2 | |
| Completed |
NCT05062759 -
Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
|
Phase 3 | |
| Completed |
NCT04307173 -
Study of Multiple Ascending Dose of KBL693 in Healthy Participants
|
Phase 1 | |
| Recruiting |
NCT05761028 -
A Study of CM310 in Subjects With Moderate to Severe Asthma
|
Phase 2/Phase 3 |